Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Insight - Telomerase: the next cancer target?

This article was originally published in Scrip

Executive Summary

In some western countries, such as the US and the UK, cancer is now overtaking cardiovascular disease as the leading cause of death. One in three people can expect to suffer cancer at some stage in their lifetime, with one in four going on to die from the disease. In developing countries, the incidence is far lower, largely due to higher mortality from infectious diseases. However, as control over the spread of diseases such as malaria and tuberculosis improves, the incidence of cancer is expected to rise in these regions.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel